by The global Antacids market size was estimated to be around US$ 7.20 billion in 2023. It is projected to reach US$ 9.64 billion by 2032, indicating a CAGR of 3.30% from 2023 to 2032.
Key Takeaways
- North America contributed the highest revenue share of 46% in 2022.
- Asia Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By the mechanism of action, the non-systemic antacid segment has held the largest market share of 70% in 2022 and is anticipated to grow at a remarkable CAGR between 2023 and 2032.
- By formulation type, the tables segment generated the highest revenue share in 2022.
- By formulation type, the liquids segment is expected to expand at the fastest CAGR over the projected period.
- By distribution channel, the drug store & retail pharmacies segment generated the highest revenue share in 2022.
- By distribution channel, the online providers segment is expected to expand at the fastest CAGR over the projected period.
The market research report on the Antacids market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Antacids products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3526
Antacids Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 7.20 Billion |
| Market Size by 2032 | USD 9.64 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 3.30% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Mechanism of Action, By Formulation Type, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Antiscalants Market Size To Reach USD 6.85 Billion By 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Antacids market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Antacids market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Antacids products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Antacids market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Antacids market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Antacids market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Antacids Market Players
- Infirst Healthcare Inc.
- Bayer AG
- Pfizer Inc.
- Abbott Laboratories
- Cipla Ltd
- Reckitt Benckiser Group PLC
- WellSpring Pharmaceutical Corporation
- Prestige Consumer Healthcare Inc.
- Alkem Laboratories Ltd.
- Haleon plc
Segments Covered in the Report
By Mechanism of Action
- Systemic Antacids
- Non-systemic Antacids
By Formulation Type
- Tablets
- Liquids
- Others
By Distribution Channel
- Hospital pharmacies
- Drug stores and retail pharmacies
- Online providers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antacids Market
5.1. COVID-19 Landscape: Antacids Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antacids Market, By Mechanism of Action
8.1. Antacids Market Revenue and Volume, by Mechanism of Action, 2023-2032
8.1.1 Systemic Antacids
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Non-systemic Antacids
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Antacids Market, By Formulation Type
9.1. Antacids Market Revenue and Volume, by Formulation Type, 2023-2032
9.1.1. Tablets
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Liquids
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Antacids Market, By Distribution Channel
10.1. Antacids Market Revenue and Volume, by Distribution Channel, 2023-2032
10.1.1. Hospital pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Drug stores and retail pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Online providers
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Antacids Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Mechanism of Action (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Formulation Type (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Infirst Healthcare Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bayer AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abbott Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cipla Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Reckitt Benckiser Group PLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WellSpring Pharmaceutical Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Prestige Consumer Healthcare Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Alkem Laboratories Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Haleon plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
